<DOC>
	<DOCNO>NCT01320982</DOCNO>
	<brief_summary>The objective study evaluate efficacy Pramipexole , Minocycline Aspirin compare placebo , add-on anti-psychotics treatment patient schizophrenia .</brief_summary>
	<brief_title>Minocycline , Acetylsalicylic Acid Pramipexole v Placebo Patients With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>Inflammatory process implicate cause schizophrenia ( Fan , Goff et al . 2007 ) , COX-2 inhibitor , Celecoxib , show reduce symptom schizophrenia ( Muller , Krause et al . 2010 ) . Aspirin , also non-steroidal anti-inflammatory drug ( NSAID ) , irreversibly inhibit Cyclooxygenase-1 ( COX-1 ) modify enzymatic activity Cyclooxygenase-2 ( COX-2 ) , thus inhibit formation prostaglandin reduce inflammatory reaction . In study fund Stanley Medical Research Institute ( SMRI ) recently publish , Laan ( Laan , Grobbee et al . 2010 ) administer add-on 1000mg/d Aspirin patient schizophrenia receive anti-psychotics , report reduction Positive negative syndrome scale ( PANSS ) total PANSS positive score without substantial side effect . Minocycline second-generation tetracycline exert anti-inflammatory antimicrobial effect distinct neuroprotective profile . Minocycline effect glutaminergic system , inhibition neuronal nitric oxide synthase ( nNOS ) block nitric oxide ( NO ) - induce neurotoxicity ( Du et al , 1998 ; Jiang et al. , 2005 ) , thus suggest potential treatment schizophrenia . One publish study ( Levkovitz , Mendlovich et al . 2010 ) , another , unpublished study Bill Deakin find add-on treatment 200mg/d Minocycline beneficial symptom cognition schizophrenia , study Miayoka et al ( Miyaoka , Yasukawa et al . 2008 ) administer open-label 450 mg/day Minocycline , find improvement positive symptom . Indirect pharmacological evidence suggest relative excess dopaminergic activity implicate pathogenesis symptom schizophrenia , effective antipsychotic effect dopamine D2 receptor . Pramipexole pre-synaptic dopamine auto-receptor agonist hypothesize improve symptom schizophrenia patient . In open label study , Kasper ( Kasper , Barnas et al . 1997 ) show statistically significant improvement PANSS score patient stabilize haloperidol . Other data indicate add-on Pramipexole improve symptom depression cognition , patient affective disorder ( Goldberg , Frye et al . 1999 ; Sporn , Ghaemi et al . 2000 ; Goldberg , Burdick et al . 2004 ; Zarate , Payne et al . 2004 ) , Malhotra et al , unpublished data . All study relatively small , performed investigator interest compound . The objective study replicate large trial investigator specific interest compound . This propose study multi-arm study , patient randomize one three study drug : Pramipexole , Minocycline Aspirin , placebo part protocol . A design several active compound compare placebo arm utilize schizophrenia ( Meltzer , Arvanitis et al . 2004 ) . This design several advantage : addition reduce cost time expose few patient placebo , enable direct comparison compound placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Male female , 1865 year age , inclusive 2 . Females abstinent practice establish method birth control ( oral contraceptive tablet , hormonal implant device , hormone patch , injectable contraceptive , intrauterine device . 3 . Willing able provide inform consent , nature study fully explain 4 . Current DSMIVTR diagnosis schizophrenia schizoaffective disorder confirm modify Structured Clinical Interview DSM Disorders ( SCID ) least 2 prior schizophrenic episode , continually ill least 6 month . 5 . Symptoms : 4 ( moderate ) Clinical Global Impression scale ( CGIS ) 4 ( moderate ) score two follow four Positive negative syndrome scale ( PANSS ) item : delusion , hallucinatory behavior , conceptual disorganization suspiciousness/ persecution , and/or total PANSS negative symptom score 18 . 6 . Must antipsychotic drug , least 2 week prior baseline visit , dos within Patient Outcome Research Team ( PORT ) criterion , whenever possible . Patients receive high dos record review insure dose require , possible , stabilize low dose prior study entry . 7 . Inpatients outpatient . Inpatients randomize 3 day admission 1 . Unwilling unable , opinion Investigator , comply study instruction 2 . Pregnant breastfeed 3 . Unstable medical disease ( malignancy , poorly control diabetes , active ischemic cardiac disease , cardiomyopathy , serious pulmonary disease , kidney disease , impair liver function . History hemorrhagic CVA peptic ulcer disease . 4 . Patients treat : trial medication i.e . pramipexole/minocycline/ acetylsalicylic acid , NSAIDs , anticoagulant , sucralfate , cimetidine , amantadine , mexiletine . 5 . Likely allergy sensitivity raloxifene/pramipexole/minocycline/acetylsalicylic acid . 6 . At significant risk commit suicide , opinion Investigator , currently imminent risk suicide harm others . 7 . Patients current DSMIV substance alcohol abuse . Patients history and/or current recreational use cannabinoids alcohol , and/or patient smoke cigarette include . 8 . Concurrent delirium , mental retardation , druginduced psychosis , history clinically significant brain trauma document CT MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
</DOC>